NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/26/2025
Back to search
Official data from USPTO
VUEBLU
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
08/27/2025
Classification
Registered
Trademark type
Combined
Nice classes
5, 10
Filing date
05/30/2023
Registration date
08/26/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/26/2025
Last transaction
08/27/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
3
Owner type
99
Owner location
Dublin 2, IE
Examiner
LADZEKPO, ASHIMADI
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the term "VUEBLUE" in dark blue with the "V" and "B" capitalized surrounded by four blue and two additional intersecting curved lines, the last two of which vary in color from yellow to orange. The color white represents background and is not a claimed feature of the mark.
Holders and representatives
Holders
Cosmo Technologies Limited
Representatives
John Pickerill FREDRIKSON & BYRON, P.A.
Technical classification
Nice Classes
Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Diagnostic agentspreparations and substances for medical and surgical purposes; Diagnostic agentspreparations and substances for medical purposesthe enhancing of adenomatouscancerous and other proliferative lesions in the colon for patients undergoing colonoscopy and for the visualization of colonic adenoma in patients undergoing screening colonoscopy including patients at high risk of colorectal carcinoma (CRC)including those with previous history of polyps at prior colonoscopypatients with colorectal cancer and patients with family history; Diagnostic reagents and contrast media for medical and surgical use; Contrast media for use with imaging medical equipment; Contrast media for use with colonoscopic equipment; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for use in colonoscopy; pharmaceutical preparations for the differentiation of the tissues of the intestines and colon and lesions thereto; pharmaceutical preparations for use in the colonoscopic diagnostic evaluation; methylene blue for pharmaceuticalmedicalsurgical and medical diagnostic purposes; dye for pharmaceuticalmedicalsurgical and medical diagnostic purposes in the nature of surgical dyes; pharmaceutical preparations for use in the endoscopic diagnostic evaluation; pharmaceutical compositions for use in endoscopy; methylene blue for pharmaceuticalmedicalsurgical and medical diagnostic purposesfor enhancing visualization during colonoscopy; dyes for pharmaceuticalmedicalsurgical and medical diagnostic purposesfor enhancing visualization during colonoscopy in the nature of surgical dyes
Class 10
Medical devices for use in chromoendoscopy and endoscopy procedures of the gastrointestinal tract; medical devices to aid the detectiondiagnosisprevention and treatment of gastroenterological diseases; medical instruments to aid the detectiondiagnosisprevention and treatment of gastroenterological diseases; medical devices for enhancing visualization during chromoendoscopyendoscopycolonoscopysigmoidoscopyanoscopyrectoscopy and proctoscopy procedures; medical devices for introducing compositions containing dye into the human body for pharmaceuticalmedicalsurgical and medical diagnostic purposes; medical devices made with dye for enhancing visualization of polypsadenomascarcinomasearly stage cancers and other lesions for pharmaceuticalmedicalsurgical and medical diagnostic purposes
Publications
History of USPTO decisions and trademark events.
32 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
08/26/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/10/2025
PUBO
PUBLISHED FOR OPPOSITION
06/10/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/04/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/07/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
05/07/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/07/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
05/07/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/07/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
05/05/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/05/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
05/05/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/05/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/08/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/07/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/07/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/07/2025
GNRT
NON-FINAL ACTION E-MAILED
01/07/2025
CNRT
NON-FINAL ACTION WRITTEN
01/07/2025
DOCK
ASSIGNED TO EXAMINER
12/04/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/01/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/01/2024
ALIE
ASSIGNED TO LIE
10/01/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
06/07/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/25/2024
GNSL
LETTER OF SUSPENSION E-MAILED
03/25/2024
CNSL
SUSPENSION LETTER WRITTEN
03/25/2024
DOCK
ASSIGNED TO EXAMINER
02/21/2024
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/30/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/29/2023
NWAP
NEW APPLICATION ENTERED
06/02/2023
Continuous trademark protection
Get notified about every new filing that threatens VUEBLU or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.